Recent major researches advancements have significantly expanded our understanding of psoriasis pathophysiology, resulting in the development of highly effective targeted therapies, such as anti‐TNFα, IL‐12/23‐inhibitors, IL‐17‐inhibitors, or IL‐23‐inhibitors. The gene discussed is IL17A; the disease is psoriasis.